Login to Your Account



Diurnal plans EMA filing on back of phase III Infacort data

By Nuala Moran
Staff Writer

Tuesday, July 12, 2016

LONDON – Endocrine specialist Diurnal Group plc turned in positive phase III results in the pivotal study of Infacort, clearing the way for the first licensed pediatric formulation of hydrocortisone for treating adrenal insufficiency to reach the market in 2017.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription